Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

f clinical trials, and the potential therapeutic and commercial potential, of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  Surgical Theater, LLC announced today ... Business Advisory Board. New members include Ori ... Business Development and New Technologies for Given Imaging ... Senior Vice President and General Manager of Philips ... flight simulation technology to brain surgery and has ...
(Date:7/28/2014)... 2014  VigeneTech, Inc, in collaboration with BioLegend, ... Analysis Software, an OEM software solution for analysis ... and offers varieties of bead-based multi-analyte immunoassay products ... of VigeneTech,s data analysis software, FCS data files ... reported LEGENDplex™ software is a ...
(Date:7/28/2014)... July 28, 2014  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Tuesday, August ... and Michael Carruthers , Chief Financial ... August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... oncology: most, actively researched disease area Researchers ... reagent performance ... Strategic Diagnostics,Inc. (Nasdaq: SDIX ) -- today announced ... reagents in support of oncology-based research and,discovery. These high-quality ...
... FASgen,s fatty acid synthase,inhibitor (FASi) compounds, led ... xenograft cell line tested, in both orthotopic,and flank ... H1975; LX7); two,ovarian; breast; and, colon. In many ... been shown in extensive preclinical studies to,be remarkably ...
Cached Medicine Technology:Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 2Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 3Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 4Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 5FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2
(Date:7/28/2014)... 2014 Parker Waichman LLP, a personal injury ... that the heroes of 9/11 are never forgotten, comments that ... important deadline. According to a VCF message dated ... cancer on or before October 12, 2012 must file a ... and others who were allegedly injured by the toxic dust ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... relieve sleep apnea in children, but a new study confirms ... if they,re already overweight. The researchers said that,s a ... of health problems -- including, ironically, sleep apnea. But they,re ... Instead, they said, doctors and parents should be aware that ...
(Date:7/28/2014)... Sarasota-based FCCI Insurance Group (FCCI) was recently ... Still headquartered in Sarasota where it was originally founded ... the top ten of the Best Large Companies category. ... August issue of Florida Trend magazine. One-hundred companies are ... #7 for 2014, FCCI has been in the top ...
(Date:7/28/2014)... for patients with one of the UK,s most common ... Chronic obstructive pulmonary disease (COPD) is the name for ... to long-term damage to the lungs. Often linked ... of all hospital admissions in the UK, with a ... they are discharged. , A team of ...
(Date:7/28/2014)... 2014 The report “Industrial Enzymes ... & Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & ... defines and segments the global industrial enzymes market ... for industrial enzymes. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ...
Breaking Medicine News(10 mins):Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4
... Tenn., Nov. 2 Brookdale Senior Living Inc. (NYSE: ... for the third quarter of 2009. , Bill ... results this quarter which build on the success of the ... operating effectively in today,s difficult environment as evidenced by our ...
... FDA NOTE TO CORRESPONDENTS , SILVER SPRING, ... Administration (FDA) today released a listing of eight recent ... products. These updates can be accessed from the agency,s ... You can sign-up for e-mail notices of new ...
... Nov. 2 The Ensign Group, Inc. (Nasdaq: ENSG ... nursing, rehabilitative care services, hospice care and assisted living companies, ... year 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) , ... , Total revenue was a record $132.9 million, up ...
... Highest Levels of BPA Were Detected in Some Samples of Green ... Levels Shown to Cause Harm in Animal Studies; FDA,s Safety Standards ... 2 Consumer Reports, latest tests of canned foods, including ... of the 19 name-brand foods tested contain measurable levels of Bisphenol ...
... patients with HER2 positive tumors one centimeter or smaller are ... those with early-stage disease who do not express the aggressive ... University of Texas M. D. Anderson Cancer Center. The ... Oncology , is the first large study to analyze this ...
... who received influenza vaccine during pregnancy were hospitalized at ... according to preliminary results of an ongoing study by ... the study October 29 at the 47th annual meeting ... Influenza is a major cause of serious ...
Cached Medicine News:Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 2Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 3Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 4Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 5Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 6Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 7Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 8Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 9Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 10Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 11Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 12Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 13Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 14Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 15Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 16Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 17Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 18Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 19Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 20Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 21Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 22Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 23Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 2Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 3Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 2Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 3Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 4Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 5Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 6Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 7Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 8Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 9Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 10Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 11Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 12
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
For primary and revision cases...
Medicine Products: